Jay F Sarthy, MD, PhD
Cancer and Blood Disorders Center, Pediatric Blood and Marrow Transplant Program
On staff since December 2017
Children's Title: Attending Physician, Pediatric Bone Marrow Transplantation Service, Cancer and Blood Disorders Center
Academic Title: Assistant Professor, Department of Pediatrics, University of Washington School of Medicine
Research Title: Investigator, Ben Towne Center for Childhood Cancer Research and Assistant Director of Epigenetics
Research Center: Ben Towne Center for Childhood Cancer Research
"My approach to care is based on building trust with you and your child. I’m there for each family through thick and thin, no matter how treatment is going or what the result is."
-
Dr. Jay Sarthy is a hematologist-oncologist who specializes in pediatric bone marrow transplantation for children with blood cancers and rare genetic conditions, such as telomere syndromes.
In addition to working closely with patients and families, Dr. Sarthy studies pediatric cancer epigenetics — how changes in the way genes function can derail normal development, giving rise to cancer. The goal is to better understand how these processes go awry and then use that knowledge to identify new treatments.
Dr. Sarthy also is a physician at Fred Hutchinson Cancer Center and an assistant professor in the Department of Pediatrics at the University of Washington School of Medicine.
-
Related Pages
-
The Sarthy Lab seeks to improve the lives of children with cancer by studying the fundamental mechanisms cancer cells use to evade therapies and develop resistance. By focusing on chromatin, the mix of proteins and DNA that are found in cells ranging from yeast to fruit flies to humans, we will understand how cancers form and identify safer ways to kill cancer cells while minimizing side effects of these often toxic therapies.
-
-
Other Publications
-
Chew GL, Bleakley M, Bradley RK, Malik HS, Henikoff S, Molaro A, Sarthy JShort H2A histone variants are expressed in cancer.
33473122 Nature communications, 2021 Jan 20 : 12(1)490 PMCID:PMC7817690 -
Vitanza NA, Biery MC, Myers C, Ferguson E, Zheng Y, Girard EJ, Przystal JM, Park G, Noll A, Pakiam F, Winter CA, Morris SM, Sarthy J, Cole BL, Leary SES, Crane C, Lieberman NAP, Mueller S, Nazarian J, Gottardo R, Brusniak MY, Mhyre AJ, Olson JMOptimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
33130903 Neuro-oncology, 2020 Nov 1 -
Sarthy JF, Meers MP, Janssens DH, Henikoff JG, Feldman H, Paddison PJ, Lockwood CM, Vitanza NA, Olson JM, Ahmad K, Henikoff SHistone deposition pathways determine the chromatin landscapes of H3.1 and H3.3 K27M oncohistones.
32902381 eLife, 2020 Sep 9 : 9 PMCID:PMC7518889 -
Vitanza NA, Khalatbari H, Ermoian R, Sarthy J, Lockwood CM, Cole BL, Leary SESMolecularly Targeted Treatments for NF1-Mutant Diffuse Intrinsic Pontine Glioma.
32862234 The journal of applied laboratory medicine, 2020 Aug 30 -
Woerner A, Shin DS, Chick JFB, Smith CA, Sarthy JF, Monroe EJEndolymphatic exclusion for the treatment of pediatric chylous ascites secondary to neuroblastoma resection: report of two cases.
32461775 Radiology case reports, 2020 July : 15(7)1044-1049 PMCID:PMC7240057 -
Zeineldin M, Federico S, Chen X, Fan Y, Xu B, Stewart E, Zhou X, Jeon J, Griffiths L, Nguyen R, Norrie J, Easton J, Mulder H, Yergeau D, Liu Y, Wu J, Van Ryn C, Naranjo A, Hogarty MD, Kamiński MM, Valentine M, Pruett-Miller SM, Pappo A, Zhang J, Clay MR, Bahrami A, Vogel P, Lee S, Shelat A, Sarthy JF, Meers MP, George RE, Mardis ER, Wilson RK, Henikoff S, Downing JR, Dyer MAMYCN amplification and ATRX mutations are incompatible in neuroblastoma.
32060267 Nature communications, 2020 Feb 14 : 11(1)913 PMCID:PMC7021759 -
Sarthy JF, Henikoff SBringing Oncohistones into the Fold.
31575564 Cancer discovery, 2019 Oct. : 9(10)1346-1348 -
Sarthy JF, Henikoff S, Ahmad KChromatin Bottlenecks in Cancer.
30898265 Trends in cancer, 2019 March : 5(3)183-194 -
Steineck A, Krumm N, Sarthy JF, Pritchard CC, Chapman T, Stacey AW, Vitanza NA, Cole BResponse to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma.
32923855 JCO precision oncology, 2019 : 3 PMCID:PMC7446378 -
Janssens DH, Wu SJ, Sarthy JF, Meers MP, Myers CH, Olson JM, Ahmad K, Henikoff SAutomated in situ chromatin profiling efficiently resolves cell types and gene regulatory programs.
30577869 Epigenetics & chromatin, 2018 Dec 21 : 11(1)74 PMCID:PMC6302505 -
Tedesco KT, Sarthy J, Pinto N, Boos MDAcute enlargement of a vascular plaque and gait changes in a young girl.
30487229 BMJ (Clinical research ed.), 2018 Nov 28 : 363k4679 -
Sarthy J, Zha J, Babushok D, Shenoy A, Fan JM, Wertheim G, Himebauch A, Munchel A, Taraseviciute A, Yang S, Shima H, Narumi S, Meshinchi S, Olson TSPoor outcome with hematopoietic stem cell transplantation for bone marrow failure and MDS with severe MIRAGE syndrome phenotype.
29365320 Blood advances, 2018 Jan 23 : 2(2)120-125 PMCID:PMC5787871 -
Sarthy JF, Reddivalla N, Radhi M, Chastain KPediatric 8p11 eosinophilic myeloproliferative syndrome (EMS): A case report and review of the literature.
27808462 Pediatric blood & cancer, 2017 May : 64(5) -
Sarthy J, DiBardino DPyogenic liver abscess caused by Streptococcus mitis.
23969218 The Lancet. Infectious diseases, 2013 Sept. : 13(9)822 -
Sarthy JF, Baumann PApollo-taking the lead in telomere protection.
20797622 Molecular cell, 2010 Aug 27 : 39(4)489-91 -
Sarthy J, Bae NS, Scrafford J, Baumann PHuman RAP1 inhibits non-homologous end joining at telomeres.
19763083 The EMBO journal, 2009 Nov 4 : 28(21)3390-9 PMCID:PMC2776107 -
Sarthy J, Gamblin TCA light scattering assay for arachidonic acid-induced tau fibrillization without interfering micellization.
16620751 Analytical biochemistry, 2006 Jun 1 : 353(1)150-2 -
Shieh CC, Trumbull JD, Sarthy JF, McKenna DG, Parihar AS, Zhang XF, Faltynek CR, Gopalakrishnan MAutomated Parallel Oocyte Electrophysiology Test station (POETs): a screening platform for identification of ligand-gated ion channel modulators.
15090238 Assay and drug development technologies, 2003 Oct. : 1(5)655-63
-
Overview
- Board Certification(s)
-
Pediatrics
Pediatric Hematology-Oncology
- Medical/Professional School
-
Northwestern University, Chicago, IL
University of Kansas at Lawrence, Lawrence, KS - Residency
-
Children's Mercy Hospital, Kansas City, MO
- Fellowship
-
University of Washington School of Medicine GME, Seattle, WA
- Clinical Interests
-
Hematopoietic stem cell transplantation
- Research Description
-
The Sarthy Lab is exploring the epigenetics of pediatric lymphomas to gain insight into how and why these cancers start, in hopes of ultimately finding better treatments. Led by Dr. Jay Sarthy, this work could shed light on why some cancers are resistant to treatment or come back after treatment. The Sarthy Lab is also examining a chemotherapy drug often used in Asia to treat elderly cancer patients to see if it could become a frontline treatment for pediatric cancers. This drug could have fewer side effects than today’s standard treatments.